JP2004537029A - 血小板／白血球相互作用アッセイ及びその試薬 - Google Patents
血小板／白血球相互作用アッセイ及びその試薬 Download PDFInfo
- Publication number
- JP2004537029A JP2004537029A JP2002542324A JP2002542324A JP2004537029A JP 2004537029 A JP2004537029 A JP 2004537029A JP 2002542324 A JP2002542324 A JP 2002542324A JP 2002542324 A JP2002542324 A JP 2002542324A JP 2004537029 A JP2004537029 A JP 2004537029A
- Authority
- JP
- Japan
- Prior art keywords
- factor
- ligand
- platelet
- leukocyte
- magnetic particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 224
- 230000003993 interaction Effects 0.000 title claims abstract description 145
- 238000003556 assay Methods 0.000 title claims abstract description 79
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 58
- 239000003446 ligand Substances 0.000 claims abstract description 143
- 239000006249 magnetic particle Substances 0.000 claims abstract description 88
- 239000007790 solid phase Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 162
- 210000004369 blood Anatomy 0.000 claims description 115
- 239000008280 blood Substances 0.000 claims description 115
- 230000005291 magnetic effect Effects 0.000 claims description 72
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 60
- 102100036537 von Willebrand factor Human genes 0.000 claims description 60
- 229960001134 von willebrand factor Drugs 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 47
- 239000003550 marker Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 33
- 239000011324 bead Substances 0.000 claims description 28
- 108010035532 Collagen Proteins 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 22
- 108010067306 Fibronectins Proteins 0.000 claims description 21
- 102000016359 Fibronectins Human genes 0.000 claims description 21
- 108010085895 Laminin Proteins 0.000 claims description 21
- 102000007547 Laminin Human genes 0.000 claims description 21
- 108010081689 Osteopontin Proteins 0.000 claims description 21
- 102000004264 Osteopontin Human genes 0.000 claims description 21
- 101150045640 VWF gene Proteins 0.000 claims description 20
- 102100035140 Vitronectin Human genes 0.000 claims description 20
- 108010031318 Vitronectin Proteins 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 18
- 238000005259 measurement Methods 0.000 claims description 18
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 16
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 16
- 108010049003 Fibrinogen Proteins 0.000 claims description 16
- 102000008946 Fibrinogen Human genes 0.000 claims description 16
- 229920002971 Heparan sulfate Polymers 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 16
- 108060002895 fibrillin Proteins 0.000 claims description 16
- 102000013370 fibrillin Human genes 0.000 claims description 16
- 229940012952 fibrinogen Drugs 0.000 claims description 16
- 230000033001 locomotion Effects 0.000 claims description 16
- 239000004793 Polystyrene Substances 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 229920002223 polystyrene Polymers 0.000 claims description 15
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 14
- 108010029144 Factor IIa Proteins 0.000 claims description 14
- 108010076282 Factor IX Proteins 0.000 claims description 14
- 108010048049 Factor IXa Proteins 0.000 claims description 14
- 108010014172 Factor V Proteins 0.000 claims description 14
- 108010054218 Factor VIII Proteins 0.000 claims description 14
- 102000001690 Factor VIII Human genes 0.000 claims description 14
- 108010061932 Factor VIIIa Proteins 0.000 claims description 14
- 108010014173 Factor X Proteins 0.000 claims description 14
- 108010074864 Factor XI Proteins 0.000 claims description 14
- 108010080865 Factor XII Proteins 0.000 claims description 14
- 102000000429 Factor XII Human genes 0.000 claims description 14
- 108010071289 Factor XIII Proteins 0.000 claims description 14
- 108010000196 Factor XIIIa Proteins 0.000 claims description 14
- 108010071241 Factor XIIa Proteins 0.000 claims description 14
- 108010080805 Factor XIa Proteins 0.000 claims description 14
- 108010074860 Factor Xa Proteins 0.000 claims description 14
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 14
- 108010094028 Prothrombin Proteins 0.000 claims description 14
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 14
- 229960004222 factor ix Drugs 0.000 claims description 14
- 229960000301 factor viii Drugs 0.000 claims description 14
- 229940012444 factor xiii Drugs 0.000 claims description 14
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 13
- 208000029078 coronary artery disease Diseases 0.000 claims description 13
- 239000011859 microparticle Substances 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 102000004506 Blood Proteins Human genes 0.000 claims description 7
- 108010017384 Blood Proteins Proteins 0.000 claims description 7
- 108060008245 Thrombospondin Proteins 0.000 claims description 7
- 102000002938 Thrombospondin Human genes 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 230000005298 paramagnetic effect Effects 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 108010035766 P-Selectin Proteins 0.000 claims description 6
- 102100023472 P-selectin Human genes 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 6
- 238000004220 aggregation Methods 0.000 claims description 6
- 230000009918 complex formation Effects 0.000 claims description 6
- 206010002388 Angina unstable Diseases 0.000 claims description 5
- 108010024212 E-Selectin Proteins 0.000 claims description 5
- 102100023471 E-selectin Human genes 0.000 claims description 5
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 5
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 5
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 5
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 5
- 108010092694 L-Selectin Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000007814 Unstable Angina Diseases 0.000 claims description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 5
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 5
- 238000004163 cytometry Methods 0.000 claims description 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 5
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 claims description 4
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000010836 blood and blood product Substances 0.000 claims description 4
- 229940125691 blood product Drugs 0.000 claims description 4
- 239000010419 fine particle Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 230000001788 irregular Effects 0.000 claims description 4
- 239000004816 latex Substances 0.000 claims description 4
- 229920000126 latex Polymers 0.000 claims description 4
- 238000000386 microscopy Methods 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000004907 flux Effects 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 238000010865 video microscopy Methods 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 239000004809 Teflon Substances 0.000 claims description 2
- 229920006362 Teflon® Polymers 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 238000004624 confocal microscopy Methods 0.000 claims description 2
- 230000005672 electromagnetic field Effects 0.000 claims description 2
- 238000002270 exclusion chromatography Methods 0.000 claims description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 230000001744 histochemical effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 108010074105 Factor Va Proteins 0.000 claims 13
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 8
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 8
- 102000016551 L-selectin Human genes 0.000 claims 3
- 230000004520 agglutination Effects 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 108050001049 Extracellular proteins Proteins 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 239000012503 blood component Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000010188 recombinant method Methods 0.000 claims 1
- 238000004626 scanning electron microscopy Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000004627 transmission electron microscopy Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 41
- 238000012360 testing method Methods 0.000 description 32
- 239000004005 microsphere Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 208000013403 hyperactivity Diseases 0.000 description 8
- 125000006850 spacer group Chemical group 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 102100025390 Integrin beta-2 Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000037273 Pathologic Processes Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000009054 pathological process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000013130 cardiovascular surgery Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000007704 wet chemistry method Methods 0.000 description 2
- 241001552669 Adonis annua Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229940034998 human von willebrand factor Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/712,165 US6586259B1 (en) | 1999-11-15 | 2000-11-15 | Platelet/leukocyte interaction assay and reagent therefor |
| PCT/US2001/042946 WO2002039949A2 (en) | 2000-11-15 | 2001-11-15 | Platelet/leukocyte interaction assay and reagent therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004537029A true JP2004537029A (ja) | 2004-12-09 |
Family
ID=24860995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002542324A Pending JP2004537029A (ja) | 2000-11-15 | 2001-11-15 | 血小板／白血球相互作用アッセイ及びその試薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6586259B1 (es) |
| EP (1) | EP1334363A2 (es) |
| JP (1) | JP2004537029A (es) |
| KR (1) | KR20030067686A (es) |
| AU (1) | AU2002233923A1 (es) |
| BR (1) | BR0115396A (es) |
| CA (1) | CA2428109A1 (es) |
| MX (1) | MXPA03004287A (es) |
| WO (1) | WO2002039949A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020072078A1 (en) * | 1999-04-28 | 2002-06-13 | Development Center For Biotechnology, A Taiwan Corporation | Rapid test for cell surface antigen |
| GB0015923D0 (en) * | 2000-06-30 | 2000-08-23 | Astrazeneca Ab | Methods |
| US20020076833A1 (en) * | 2000-08-01 | 2002-06-20 | Henry Michael R. | Analysis of biological samples utilizing a coated solid phase |
| DE10122806A1 (de) * | 2001-05-10 | 2002-11-14 | Holger Kiesewetter | Verfahren zum Nachweis von Blutzell-Antigenen und gegen diese gerichtete Antikörper |
| US8697029B2 (en) * | 2002-04-18 | 2014-04-15 | The Regents Of The University Of Michigan | Modulated physical and chemical sensors |
| US6852547B2 (en) * | 2002-08-01 | 2005-02-08 | Arizona Board Of Regents | Dynamically formed rotors for lock-in amplifier detection |
| JP2005538383A (ja) | 2002-09-10 | 2005-12-15 | プラコア・インコーポレーテッド | 血小板機能を監視する方法および装置 |
| US7439069B2 (en) * | 2004-02-27 | 2008-10-21 | Nippoldt Douglas D | Blood coagulation test cartridge, system, and method |
| US7422905B2 (en) * | 2004-02-27 | 2008-09-09 | Medtronic, Inc. | Blood coagulation test cartridge, system, and method |
| US7399637B2 (en) * | 2004-04-19 | 2008-07-15 | Medtronic, Inc. | Blood coagulation test cartridge, system, and method |
| EP1875232A2 (en) * | 2005-04-25 | 2008-01-09 | PlaCor, Inc. | Methods and devices for monitoring platelet function |
| US8124779B2 (en) * | 2005-12-05 | 2012-02-28 | Astrazeneca Ab | Process for the preparation of esomeprazole non-salt form |
| US7867765B2 (en) * | 2005-12-28 | 2011-01-11 | The General Hospital Corporation | Blood cell sorting methods and systems |
| US20100099130A1 (en) * | 2006-10-25 | 2010-04-22 | Placor Inc. | Methods and devices for monitoring platelet function |
| US9068977B2 (en) * | 2007-03-09 | 2015-06-30 | The Regents Of The University Of Michigan | Non-linear rotation rates of remotely driven particles and uses thereof |
| US20110177592A1 (en) * | 2008-07-11 | 2011-07-21 | Faustman Denise L | Magnetic apparatus for blood separation |
| US20110195487A1 (en) * | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Sample container for biomarker maintenance |
| WO2011127467A1 (en) * | 2010-04-09 | 2011-10-13 | Companion Diagnostics, Inc. | Devices, systems, and methods for biomarker stabilization |
| WO2012027747A2 (en) | 2010-08-27 | 2012-03-01 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation sensing systems and methods |
| WO2012142179A2 (en) | 2011-04-11 | 2012-10-18 | The Regents Of The University Of Michigan | Magnetically induced microspinning for super-detection and super-characterization of biomarkers and live cells |
| CA2908622A1 (en) * | 2012-04-18 | 2013-10-24 | Hemoshear, Llc | In vitro model for pathological or physiologic conditions |
| US9797817B2 (en) | 2012-05-03 | 2017-10-24 | The Regents Of The University Of Michigan | Multi-mode separation for target detection |
| WO2015061372A1 (en) | 2013-10-21 | 2015-04-30 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
| US10823743B1 (en) | 2013-10-28 | 2020-11-03 | Ifirst Medical Technologies, Inc. | Methods of measuring coagulation of a biological sample |
| US9983110B2 (en) | 2013-11-04 | 2018-05-29 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation (AMBR) microviscometer for analysis of analytes |
| JP2021501322A (ja) * | 2017-10-26 | 2021-01-14 | エッセンリックス コーポレーション | 血小板の高速測定法 |
| JP2021501321A (ja) * | 2017-10-26 | 2021-01-14 | エッセンリックス コーポレーション | 組織および細胞染色のためのデバイスおよび方法 |
| KR102150803B1 (ko) | 2019-10-29 | 2020-09-02 | (주)바이오액츠 | 전혈분석을 위한 신규 형광 화합물 및 이의 제조방법 |
| KR20220076995A (ko) * | 2020-12-01 | 2022-06-08 | 재단법인대구경북과학기술원 | 세포, 미세입자 동시 분리 장치 및 그 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2467301A (en) * | 1945-07-23 | 1949-04-12 | Sperry Prod Inc | Supersonic inspection for flaws lying near the surface of apart |
| US4115535A (en) * | 1977-06-22 | 1978-09-19 | General Electric Company | Diagnostic method employing a mixture of normally separable protein-coated particles |
| US5110727A (en) * | 1987-04-03 | 1992-05-05 | Cardiovascular Diagnostics, Inc. | Method for performing coagulation assays accurately, rapidly and simply, using dry chemical reagents and paramagnetic particles |
| US5145784A (en) * | 1988-05-04 | 1992-09-08 | Cambridge Biotech Corporation | Double capture assay method employing a capillary flow device |
| US5340719A (en) * | 1990-11-23 | 1994-08-23 | Corporation Coulter | Method and apparatus for optically screening microscopic cells |
| AU671816B2 (en) * | 1992-02-08 | 1996-09-12 | Genera Technologies Limited | Methods of analysis |
| US5427913A (en) * | 1992-12-03 | 1995-06-27 | Alberta Cancer Board | Methods for determining platelet function |
| AU689768B2 (en) * | 1993-02-17 | 1998-04-09 | Cardiovascular Diagnostics, Inc. | Dry chemistry cascade immunoassay and affinity assay |
| US5670329A (en) * | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
| US5503982A (en) * | 1993-09-30 | 1996-04-02 | Research Corporation Technologies, Inc. | Detection of an acute myocardial infarction in a patient |
| US5763199A (en) * | 1994-09-29 | 1998-06-09 | Mount Sinai School Of Medicine Of The City University Of New York | Platelet blockade assay |
-
2000
- 2000-11-15 US US09/712,165 patent/US6586259B1/en not_active Expired - Fee Related
-
2001
- 2001-11-15 EP EP01984919A patent/EP1334363A2/en not_active Withdrawn
- 2001-11-15 JP JP2002542324A patent/JP2004537029A/ja active Pending
- 2001-11-15 MX MXPA03004287A patent/MXPA03004287A/es unknown
- 2001-11-15 CA CA002428109A patent/CA2428109A1/en not_active Abandoned
- 2001-11-15 BR BR0115396-0A patent/BR0115396A/pt not_active Application Discontinuation
- 2001-11-15 WO PCT/US2001/042946 patent/WO2002039949A2/en active Search and Examination
- 2001-11-15 KR KR10-2003-7006601A patent/KR20030067686A/ko not_active Application Discontinuation
- 2001-11-15 AU AU2002233923A patent/AU2002233923A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002039949A2 (en) | 2002-05-23 |
| MXPA03004287A (es) | 2003-08-19 |
| WO2002039949A9 (en) | 2003-02-06 |
| US6586259B1 (en) | 2003-07-01 |
| EP1334363A2 (en) | 2003-08-13 |
| CA2428109A1 (en) | 2002-05-23 |
| WO2002039949A3 (en) | 2002-07-18 |
| KR20030067686A (ko) | 2003-08-14 |
| BR0115396A (pt) | 2004-02-03 |
| AU2002233923A1 (en) | 2002-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6586259B1 (en) | Platelet/leukocyte interaction assay and reagent therefor | |
| Varon et al. | A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions | |
| Yuana et al. | Pre-analytical and analytical issues in the analysis of blood microparticles | |
| Enjeti et al. | Detection and measurement of microparticles: an evolving research tool for vascular biology | |
| Van der Meel et al. | Toward routine detection of extracellular vesicles in clinical samples | |
| US20040009471A1 (en) | Methods and kits for detecting a target cell | |
| US8163151B2 (en) | Assays for detection of Von Willebrand factor (vWF) multimers and for degradation of vWF by agents such as Adamts13 and related methods | |
| US20140308680A1 (en) | Method for detection of coagulation activity and biomarkers | |
| Sanak et al. | Assessment of hemocompatibility of materials with arterial blood flow by platelet functional tests | |
| EP3361254B1 (en) | Detection of endothelial disease | |
| US20020076833A1 (en) | Analysis of biological samples utilizing a coated solid phase | |
| JP4824261B2 (ja) | ＧＰＩＩｂ／ＩＩＩａレセプターアンタゴニストの簡易薬剤監視法 | |
| ES2826394T3 (es) | Ensayo de activación para el diagnóstico de una trombocitopenia inducida por heparina | |
| CA2408850A1 (en) | Platelet function assay and reagent therefor | |
| US20030211551A1 (en) | Platelet function assay and reagent therefor | |
| EP1397388B1 (en) | Fxiii subunit a detection for verifying serum sample | |
| US20020127741A1 (en) | Free Analyte detection system | |
| Lacroix et al. | Flow cytometry | |
| JP3618797B2 (ja) | 免疫測定法 | |
| Ingerslev et al. | New approaches in the measurement of coagulation | |
| US20230280359A1 (en) | Global test for determining the status of the blood coagulation system | |
| Mousa | In vitro methods of evaluating antithrombotics and thrombolytics | |
| Taylor | Laboratory management of the bleeding patient | |
| Williams et al. | Laboratory Evaluation of Hemostasis | |
| TZ et al. | 25June 2015 (25.06. 2015) VJ i F3 O| PCT |